IMPEDIMED LIMITED — Capital/Financing Update 2009

Nov 11, 2009

12[th] November 2009

==> picture [109 x 105] intentionally omitted <==

----- Start of picture text -----

ASX : IPD
----- End of picture text -----

PRESS RELEASE

IMPEDIMED ANNOUNCES CATEGORY 1 CURRENT PROCEDURAL TERMINOLOGY (CPT) CODE APPLICATION FILING WITH THE AMERICAN MEDICAL ASSOCIATION

ImpediMed Limited announced today that an application for a Category 1 Current Procedural Terminology (CPT) Code has been filed with the American Medical Association. Sponsoring the application was a prominent US based surgeon. The CPT application seeks assignment of a dedicated code that can be used by physicians across the US in billing health insurance providers for their utilization of the company’s L-Dex® technology in the prospective management of breast cancer patients at risk of lymphoedema.

Commenting on the CPT application, ImpediMed CEO Greg Brown said, “We are honoured to have such an accomplished US surgeon sponsor this important milestone in applying for a category one reimbursement code. ImpediMed’s plan to drive lymphoedema education and adoption of pre-emptive care for all patients will be greatly enhanced should this code be successful. Surgeons are the key to facilitating pre-emptive care and it is great to see their support of a Category 1 code for the L-Dex test. It demonstrates a clear commitment to protecting the quality of life of patients.”

The United States CPT coding process is the mechanism by which new technologies are assigned codes used by US public and private health insurance companies to describe the procedures and services offered by clinicians. The AMA’s CPT Editorial Panel considers and evaluates new coding requests three times each year. This coding application will be brought in front of the panel during their February 2010 meeting. New CPT 1 codes then go on for the determination of a national reimbursement payment level which is assigned to each new code. This process with the ‘relative units committee’ (RUC) can take a further few months before payment is set. All new codes become effective January 1st of the following year (2011).

For further information contact:

Greg Brown ImpediMed CEO +61-7-3860-3700

1/2

L-Dex[®] is a trademark of ImpediMed Limited.

“ L-Dex[® ] values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.

2/2